Biologics Biocon picked ₹1,125-crore ($150 million) investment from Goldman Sachs, an American International Investment Bank. “This transaction is a part of the overall strategic plan of value creation for our shareholders through Biocon Biologics,” said Kiran Mazumdar Shaw, the Executive Chairperson of Biocon.
On the development Kiran Mazumdar Shaw said, “We are extremely pleased to welcome a capital injection by Goldman Sachs at this inflection point of Biocon Biologics’ journey in its quest for global leadership in providing affordable access through Biosimilar drugs.
Also Read: Entrepreneurship Lessons From Kiran Mazumdar Shaw
Biocon is India’s largest biopharmaceutical company and Biocon Biologics provides affordable access to life-saving drugs to patients worldwide through biosimilar drugs (similar to biological medicines but more affordable).
Kiran Mazumdar Shaw is considered a pioneer in her field for building a phenomenal pharma and research business. Not long ago, Biocon Biologics became the only Indian company to provide affordable access to three biosimilar drugs to the patients in America. Shaw hopes to use funds to funnel more investments into research. “This capital injection by Goldman Sachs will enable us to make prudent investments in R&D, high-quality manufacturing, as well as, establish a global commercial footprint.”
Shaw’s leadership style is non-interfering and on-point. She continues to inspire young women to live life on their own terms and pick careers of their choice. “One of my objectives when I started Biocon was to make sure that I create a company for women scientists to pursue a vocation.”